Physician profile
David Pinn
NPI 1992048722
$5,534.43
in general payments reported to CMS, 2019-2025
29 companies · $913 in 2025
The $913 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $482 · 2021: $799 · 2022: $885 · 2023: $1,029 · 2024: $1,303 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,148 · Education: $97.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,147.54 |
| Education | $97.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,478.63 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,055.09 | 2020-2025 | Trulance, Xifaxan, Plenvu |
| Janssen Biotech, INC. | $504.04 | 2020-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $344.33 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $314.53 | 2020-2025 | Entyvio, Gattex, Eohilia |
| Ironwood Pharmaceuticals, INC | $210.65 | 2020-2022 | |
| Genzyme Corporation | $163.46 | 2022-2024 | |
| Ardelyx, INC. | $160.99 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $160.31 | 2019-2024 | Dificid, Zinplava |
| Pfizer INC. | $159.07 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $146.21 | 2020-2025 | |
| Aimmune Therapeutics, INC. | $129.90 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $106.68 | 2024-2025 | Vegzelma, Zymfentra |
| Ferring Pharmaceuticals INC. | $73.99 | 2019-2024 | Rebyota |
| Laborie Medical Technologies Corp. | $51.75 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $50.81 | 2021-2024 | Sucraid |
| Blueprint Medicines Corporation | $50.51 | 2024-2025 | Ayvakit |
| Phathom Pharmaceuticals, INC. | $47.34 | 2025 | Voquezna |
| Redhill Biopharma INC. | $43.81 | 2021-2023 | Talicia |
| Biocon Biologics INC | $38.95 | 2025 | Yesintek |
| Ethicon US, LLC | $38.62 | 2021 | |
| Novo Nordisk INC | $36.94 | 2025 | Wegovy |
| Lilly USA, LLC | $35.61 | 2024 | Omvoh |
| Anx Robotica Corp | $31.98 | 2025 | |
| Ucb, INC. | $28.25 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $19.17 | 2022 | |
| Gilead Sciences, INC. | $19.14 | 2025 | |
| Alnylam Pharmaceuticals INC. | $17.17 | 2020 | |
| Madrigal Pharmaceuticals | $16.50 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.